中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2013年
1期
65-68
,共4页
薛冬%何小舟%许贤林%周萃星%徐宁
薛鼕%何小舟%許賢林%週萃星%徐寧
설동%하소주%허현림%주췌성%서저
铁调节蛋白%前列腺癌%骨转移
鐵調節蛋白%前列腺癌%骨轉移
철조절단백%전렬선암%골전이
Hepcidin%Prostate cancer%Bone metastasis
目的 观察前列腺癌骨转移患者血清中IL-6、sTfR、BMP6等指标的变化,分析3个指标之间的相关性,探讨Hepcidin蛋白在前列腺癌骨转移中的作用.方法 选取2012年1月至2012年3月前列腺癌骨转移患者25例、前列腺癌无骨转移患者30例和BPH患者30例,年龄55～75岁,平均67岁.前列腺癌骨转移组PSA 20.0～1500.0 μg/L,中位数138.0μg/L;无骨转移组PSA 3.5 ～28.2 μg/L,中位数10.2μg/L; BPH组PSA 0.3～14.2 μg/L,中位数3.7 μg/L.采用竞争性同相酶联免疫分析法(ELISA)分别测定血清Hepcidin、IL-6、sTfR、BMP6的表达.结果 前列腺癌骨转移组、无骨转移组、BPH组血清Hepcidin含量分别为(67.7±40.6)、(37.5±15.3)、(34.3±10.7) μg/L,IL-6含量分别为(22.5±22.1)、(12.6±10.2)、(10.2±8.4)μg/L,sTfR含量分别为(5.7±2.6)、(7.9±3.6)、(8.2±5.7)μg/L,BMP6含量分别为(429.3±188.4)、(325.7±40.3)、(296.5±38.7) μg/L,血常规Hb(131.1±13.6)、(137.8±12.3)、(141.9±11.4)g/L.前列腺癌骨转移组各项检查指标与无骨转移组和BPH组比较差异均有统计学意义(P＜0.05).骨转移组Hepcidin与IL-6、sTfR、BMP6表达有相关性,相关系数分别为0.972、-0.987、0.971,差异均有统计学意义(P＜0.05)；与Hb无相关性,相关系数为0.201,差异无统计学意义(P＞0.05).结论 前列腺癌骨转移患者的血清Hepcidin表达增高,可以作为晚期前列腺癌骨转移诊断以及预后判断的敏感指标.
目的 觀察前列腺癌骨轉移患者血清中IL-6、sTfR、BMP6等指標的變化,分析3箇指標之間的相關性,探討Hepcidin蛋白在前列腺癌骨轉移中的作用.方法 選取2012年1月至2012年3月前列腺癌骨轉移患者25例、前列腺癌無骨轉移患者30例和BPH患者30例,年齡55～75歲,平均67歲.前列腺癌骨轉移組PSA 20.0～1500.0 μg/L,中位數138.0μg/L;無骨轉移組PSA 3.5 ～28.2 μg/L,中位數10.2μg/L; BPH組PSA 0.3～14.2 μg/L,中位數3.7 μg/L.採用競爭性同相酶聯免疫分析法(ELISA)分彆測定血清Hepcidin、IL-6、sTfR、BMP6的錶達.結果 前列腺癌骨轉移組、無骨轉移組、BPH組血清Hepcidin含量分彆為(67.7±40.6)、(37.5±15.3)、(34.3±10.7) μg/L,IL-6含量分彆為(22.5±22.1)、(12.6±10.2)、(10.2±8.4)μg/L,sTfR含量分彆為(5.7±2.6)、(7.9±3.6)、(8.2±5.7)μg/L,BMP6含量分彆為(429.3±188.4)、(325.7±40.3)、(296.5±38.7) μg/L,血常規Hb(131.1±13.6)、(137.8±12.3)、(141.9±11.4)g/L.前列腺癌骨轉移組各項檢查指標與無骨轉移組和BPH組比較差異均有統計學意義(P＜0.05).骨轉移組Hepcidin與IL-6、sTfR、BMP6錶達有相關性,相關繫數分彆為0.972、-0.987、0.971,差異均有統計學意義(P＜0.05)；與Hb無相關性,相關繫數為0.201,差異無統計學意義(P＞0.05).結論 前列腺癌骨轉移患者的血清Hepcidin錶達增高,可以作為晚期前列腺癌骨轉移診斷以及預後判斷的敏感指標.
목적 관찰전렬선암골전이환자혈청중IL-6、sTfR、BMP6등지표적변화,분석3개지표지간적상관성,탐토Hepcidin단백재전렬선암골전이중적작용.방법 선취2012년1월지2012년3월전렬선암골전이환자25례、전렬선암무골전이환자30례화BPH환자30례,년령55～75세,평균67세.전렬선암골전이조PSA 20.0～1500.0 μg/L,중위수138.0μg/L;무골전이조PSA 3.5 ～28.2 μg/L,중위수10.2μg/L; BPH조PSA 0.3～14.2 μg/L,중위수3.7 μg/L.채용경쟁성동상매련면역분석법(ELISA)분별측정혈청Hepcidin、IL-6、sTfR、BMP6적표체.결과 전렬선암골전이조、무골전이조、BPH조혈청Hepcidin함량분별위(67.7±40.6)、(37.5±15.3)、(34.3±10.7) μg/L,IL-6함량분별위(22.5±22.1)、(12.6±10.2)、(10.2±8.4)μg/L,sTfR함량분별위(5.7±2.6)、(7.9±3.6)、(8.2±5.7)μg/L,BMP6함량분별위(429.3±188.4)、(325.7±40.3)、(296.5±38.7) μg/L,혈상규Hb(131.1±13.6)、(137.8±12.3)、(141.9±11.4)g/L.전렬선암골전이조각항검사지표여무골전이조화BPH조비교차이균유통계학의의(P＜0.05).골전이조Hepcidin여IL-6、sTfR、BMP6표체유상관성,상관계수분별위0.972、-0.987、0.971,차이균유통계학의의(P＜0.05)；여Hb무상관성,상관계수위0.201,차이무통계학의의(P＞0.05).결론 전렬선암골전이환자적혈청Hepcidin표체증고,가이작위만기전렬선암골전이진단이급예후판단적민감지표.
Objective To detect the expression and correlation of serum Hepcidin,IL-6,sTfR,BMP6 diversity and explore the role of serum Hepcidin in prostate cancer with bone metastasis.Methods From January 2012 to March 2012,serum Hepcidin,IL-6,sTfR,BMP6 diversity were tested by ELISA in 25 prostate cancer patients with bone metastasis,30 prostate cancer patients without bone metastasis and 30 patients with BPH were used as the control group.The mean patient's age was 67 years (range from 55 to 75 years).In prostate cancers with bone metastasis group,the mean PSA base line was 138.0 μg/L (ranged from 20.0-1500 μg/L),the prostate cancers without bone metastasis group,mean PSA was 10.2 μg/L(ranged from 3.5-28.2 μg/L),and in BPH group,the mean PSA was 3.7 μg/L (ranged from 0.3-14.2 μg/L).Venous blood samples were taken in fasting mornings,then stored 3 ml in EDTA anticoagulant vacuum tube and centrifuged at4 ℃ for 10 min,the isolated serum were then preserved in-80 ℃ refrigerator.The competitive in-phase enzyme-linked immunoassay (ELISA) was used to detect serum Hepcidin,IL-6 and sTfR and BMP6 levels.Results Serum Hepcidin expressions in three groups were 67.7 ± 40.6 μg/L,37.5 ± 15.3 μg/L and 34.3 ± 10.7 μg/L,respectively.For prostate cancers with bone metastasis group,serum Hepcidin expression were higher than control group (P ＜ 0.05),and associated with IL-6(22.5 ±22.1 μg/L),sTfR (5.7 ± 2.6 μg/L),BMP6 (429.3 ± 188.4 μg/L),correlation coefficients were 0.972,-0.987,0.971 (P ＜ 0.05).Conclusions Increased serum Hepcidin level might be a sensitive index for diagnosis and prognosis of prostate cancers with bone metastasis.
